Telerehabilitation in Alzheimer's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Online cognitive telerehabilitation, VRRS tablet.
- Who it may be relevant to
- Registry conditions: Alzheimer. Basic parameters: 50 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Home-based Virtual Reality Cognitive Training as an add-on to Telerehabilitation in Alzheimer's Disease: Validation of a Protocol to Slow Down Cognitive Decline and Reduce Caregivers' Burden
Overview
Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health. In this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.
Detailed description
This project aims to use new technologies and telemedicine to ensure continuity of care and slow cognitive decline in patients with Alzheimer's disease (AD). The investigators also aim to reduce caregiver burden and healthcare costs for the national healthcare system.
The investigators hypothesize that patients provided with a VRRS tablet and undergoing autonomous cognitive training as an adjunct to cognitive telerehabilitation will achieve better cognitive outcomes than patients who do not receive a VRRS tablet.
The investigators also hypothesize that patients receiving both forms of cognitive training-autonomous training using the VRRS tablet combined with online cognitive telerehabilitation supervised by a professional neuropsychologist-will show greater improvements in cognitive function than patients who do not receive online cognitive telerehabilitation.
This is a prospective, interventional, randomized, single-blind, monocentric clinical study.
Study population: 48 patients with AD (MMSE score 18-24) and one caregiver for each patient (48 caregivers in total).
To minimize potential bias, the neuropsychologist responsible for patient and caregiver assessments will be blinded to treatment allocation.
Patients will be randomized in a 1:1:1 ratio to one of the following treatment groups:
* Intervention Group 1:\*\* 16 patients provided with a VRRS tablet to perform autonomous home-based cognitive training (5 days per week), in addition to online cognitive telerehabilitation sessions supervised by a neuropsychologist at San Raffaele Hospital twice weekly. * Intervention Group 2:\*\* 16 patients provided with a VRRS tablet to perform autonomous home-based cognitive training (5 days per week), without neuropsychologist-supervised cognitive telerehabilitation. * Comparator Group 3:\*\* 16 patients receiving online cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly. These patients will not receive a VRRS tablet for home use.
No interim analysis is planned.
Study design:
Each group will undergo a 3-month intervention according to the following schedule.
Group 1:
Autonomous home-based cognitive training using the VRRS tablet for 1 hour per day, 5 days per week.
Remote cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly.
Group 2:
Autonomous home-based cognitive training using the VRRS tablet for 1 hour per day, 5 days per week.
No cognitive telerehabilitation sessions.
Group 3:
Remote cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly.
No VRRS tablet and no additional autonomous home-based cognitive training.
\- Study visits:
Patients and caregivers will attend the following visits:
1. Enrolment. 2. Screening (Day 1) and treatment initiation. 3. Post-treatment assessment (after 3 months of treatment). 4. Follow-up assessment (3 months after completion of treatment).
* Methods of data collection
The following data will be collected:
* patients' neuropsychological performance; * electroencephalographic (EEG) activity; * caregivers' mental health and caregiver burden; * system usability; * costs associated with telerehabilitation and cognitive training. * Assessment of patients' neuropsychological performance:
Patients will undergo a comprehensive neuropsychological assessment at three time points: baseline, after the 3-month treatment period, and at the 3-month follow-up.
The assessment battery will include:
* Montreal Cognitive Assessment (MoCA) (primary outcome): a screening tool for cognitive impairment providing a total score and six domain-specific index scores (Memory, Executive Function, Attention, Language, Visuospatial Ability, and Orientation). Total scores range from 0 to 30, with scores ≥26 generally considered normal. * Mini-Mental State Examination (MMSE). * Quality of Life in Alzheimer's Disease (QoL-AD). * Geriatric Depression Scale (GDS). * Attention Matrices. * Raven's Progressive Matrices. * Token Test. * Semantic Fluency Test. * Phonemic Fluency Test. * Naming Test. * Word-Picture Naming Test. * Digit Span Test (forward and backward). * Corsi Block-Tapping Test. * Rey Complex Figure Test. * Trail Making Test. * EEG assessment:
Five minutes of resting-state EEG will be recorded using 32-channel EEG caps before and after the intervention to perform time-frequency analyses.
* Assessment of caregivers' mental health and burden: * Beck Depression Inventory-II (BDI-II). * Zarit Burden Interview.
Assessment of system usability:
System Usability Scale (SUS). Usability will be evaluated in terms of effectiveness, efficiency, and user satisfaction.
\- Assessment of the costs of telerehabilitation and cognitive training:
The following cost components will be analysed:
* healthcare professional costs (neuropsychologist); * outpatient clinic costs; * telemedicine equipment costs for both patients and the hospital; * patients' travel costs; * cognitive training equipment costs; * caregiver burden; * system usability.
Any future research involving the collected data will require prior approval from the Ethics Committee (EC).
Interventions
- Device Online cognitive telerehabilitation
Online sessions of cognitive telerehabilitation, twice a week, supervised by a neuropsychologist based at the San Raffaele hospital. - Device VRRS tablet
Patients equipped with VRRS tablets to undergo autonomous home-based cognitive training (5 days a week).
Primary outcome measures
- Montreal Cognitive Assessment (MoCA) [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
Secondary outcome measures (12)
- Electroencephalographic (EEG) activity [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Caregivers' mental status [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Caregivers' burden [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- System usability [Time frame: At the end of the 3-month rehabilitation period.]
- Telerehabilitation's costs [Time frame: At 3 months follow-up.]
- Mini Mental State Examination (MMSE) [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Quality of Live in Alzheimer's Disease (QoL-AD) [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Geriatric Depression Scale (GDS) [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Attention matrices [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Raven's Progressive Matrices (RPM) [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Token test [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
- Semantic and phonemic fluency [Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.]
Eligibility criteria
Inclusion criteria for patients with Alzheimer's disease (AD):
- Age between 50 and 90 years.
- Diagnosis of Alzheimer's disease according to established diagnostic criteria.
- Mini-Mental State Examination (MMSE) score between 18 and 24.
- Stable pharmacological treatment for at least 3 months before enrolment.
- Ability and willingness to provide written informed consent.
Inclusion criteria for caregivers:
- Age ≥18 years.
- Availability to assist the patient throughout the study.
- Ability and willingness to provide written informed consent.
Exclusion criteria for patients with Alzheimer's disease (AD):
- Refusal or inability to provide written informed consent.
- History of psychiatric disorders.
- Significant cerebrovascular disease.
- Severe visual or hearing impairment that could interfere with study procedures.
- Psychosis.
- Major depressive disorder.
- Alcohol or substance abuse.
- Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.
- Concurrent participation in another interventional pharmacological clinical trial.
- Any contraindication to undergoing EEG recording.
Exclusion criteria for caregivers:
- Refusal or inability to provide written informed consent.
- History of psychiatric disorders.
- Major depressive disorder.
- Alcohol or substance abuse.
- Use of psychotropic medications that may interfere with neuropsychological assessment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Gatica-Rojas V, Mendez-Rebolledo G. Virtual reality interface devices in the reorganization of neural networks in the brain of patients with neurological diseases. Neural Regen Res. 2014 Apr 15;9(8):888-96. doi: 10.4103/1673-5374.131612. PMID 25206907
- Yang JG, Thapa N, Park HJ, Bae S, Park KW, Park JH, Park H. Virtual Reality and Exercise Training Enhance Brain, Cognitive, and Physical Health in Older Adults with Mild Cognitive Impairment. Int J Environ Res Public Health. 2022 Oct 15;19(20):13300. doi: 10.3390/ijerph192013300. PMID 36293881
- Laver KE, George S, Thomas S, Deutsch JE, Crotty M. Virtual reality for stroke rehabilitation. Cochrane Database Syst Rev. 2015 Feb 12;2015(2):CD008349. doi: 10.1002/14651858.CD008349.pub3. PMID 25927099
- Buschert V, Bokde AL, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol. 2010 Sep;6(9):508-17. doi: 10.1038/nrneurol.2010.113. Epub 2010 Aug 17. PMID 20717104
- Emedoli D, Houdayer E, Della Rosa PA, Zito A, Brugliera L, Cimino P, Padul JD, Tettamanti A, Iannaccone S, Alemanno F. Continuity of care for patients with dementia during COVID-19 pandemic: flexibility and integration between in-person and remote visits. Front Public Health. 2024 Jan 8;11:1301949. doi: 10.3389/fpubh.2023.1301949. eCollection 2023. PMID 38259745
- Emedoli D, Alemanno F, Houdayer E, Brugliera L, Iannaccone S, Tettamanti A. Mobile application tool for remote rehabilitation after discharge from coronavirus disease-19 rehabilitation unit. Healthc Technol Lett. 2022 Aug 8;9(4-5):70-76. doi: 10.1049/htl2.12033. eCollection 2022 Aug-Oct. PMID 36225346
- Elbaz S, Cinalioglu K, Sekhon K, Gruber J, Rigas C, Bodenstein K, Naghi K, Lavin P, Greenway KT, Vahia I, Rej S, Sekhon H. A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services? Front Neurol. 2021 Dec 14;12:761965. doi: 10.3389/fneur.2021.761965. eCollection 2021. PMID 34970210
- Grabher BJ. Effects of Alzheimer Disease on Patients and Their Family. J Nucl Med Technol. 2018 Dec;46(4):335-340. doi: 10.2967/jnmt.118.218057. Epub 2018 Aug 23. PMID 30139888
Identifiers
NCT: NCT07722169 · RF-2024-12380126 VRTAD